Taiwan FDA registration 76749791b38f1c2349f043d38f8da8a6
"Kabi" Louvre Cell Treatment Kit
TW: “卡比” 羅浮細胞處理套組
Taiwan·Risk Class 2·Fresenius Kabi AG;; Fenwal International, Inc.·Registered Apr 19, 2021 – Apr 19, 2026ExpiredRegistration details
- Analysis ID
- 76749791b38f1c2349f043d38f8da8a6
- Customs Code
- DHA05603439603
Company information
- Manufacturer
- Fresenius Kabi AG;; Fenwal International, Inc.
- Manufacturer Country
- Dominican Republic;;Germany
- Authorized Representative
- FRESENIUS KABI TAIWAN LIMITED
Product details
- Intended Use
- This product is a single-use kit for the separation and preparation of blood components.
- Product Type (Level 1)
- B Hematology, pathology, and genetics
- Product Type (Level 2)
- B.9245 Automated hemocytoseparator
- Import Information
- Input;; QMS/QSD
Dates and status
- Registration Date
- Apr 19, 2021
- Expiry Date
- Apr 19, 2026
About this record
Access comprehensive regulatory information for "Kabi" Louvre Cell Treatment Kit in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 76749791b38f1c2349f043d38f8da8a6 and manufactured by Fresenius Kabi AG;; Fenwal International, Inc.. The authorized representative in Taiwan is FRESENIUS KABI TAIWAN LIMITED.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices